The leptin receptor (LEPR), also known as the obesity receptor (OB-R), is a type I cytokine receptor that binds the hormone leptin. It is encoded by the LEPR gene located on chromosome 1p31 in humans. The receptor exists in multiple isoforms generated through alternative splicing, including a long signaling form (LEPRb) and several short forms (e.g., LEPRa, LEPRc) that lack intracellular signaling domains.
Structure
- The extracellular domain contains several conserved motifs typical of cytokine receptors, such as the cytokine receptor homology (CRH) domain and immunoglobulin‑like loops that mediate ligand binding.
- The transmembrane region spans the plasma membrane, anchoring the receptor.
- The intracellular domain of the long isoform (LEPRb) possesses conserved Box1 and Box2 motifs that recruit Janus kinase 2 (JAK2), enabling downstream signaling.
Function
- Binding of leptin to LEPRb activates JAK2, which phosphorylates specific tyrosine residues on the receptor intracellular tail. This creates docking sites for signaling proteins, including STAT3, STAT5, and SH2 domain‑containing proteins.
- Activated STAT3 translocates to the nucleus to regulate transcription of appetite‑suppressing neuropeptides (e.g., pro‑opiomelanocortin) and other metabolic genes, thereby reducing food intake and increasing energy expenditure.
- Short isoforms may modulate leptin availability and transport, and can act as leptin-binding proteins in circulation.
Physiological Role
- The leptin‑LEPR signaling axis is central to the regulation of body weight, energy homeostasis, and reproductive function.
- Disruption of LEPR signaling leads to severe obesity, hyperphagia, and metabolic disturbances in both animal models and humans.
Clinical Significance
- Mutations in the LEPR gene cause monogenic obesity, often presenting in early childhood with hyperphagia and high circulating leptin levels.
- Polymorphisms in LEPR have been investigated for associations with obesity, type 2 diabetes, and cardiovascular disease, though the effect sizes are generally modest.
- Therapeutic strategies targeting the leptin‑LEPR pathway include leptin analogs, leptin sensitizers, and experimental agents designed to enhance downstream signaling.
Research Applications
- LEPR knockout mice (db/db) and rats are widely used models to study obesity, insulin resistance, and related metabolic disorders.
- Cellular assays employing LEPR‑expressing cell lines facilitate the study of cytokine‑type signaling mechanisms and drug screening.
References (representative)
- Friedman, J.M., & Halaas, J.L. (1998). Leptin and the regulation of body weight in mammals. Nature, 395(6704), 763‑770.
- Chen, H., et al. (2000). Structure–function analysis of leptin receptors. Journal of Biological Chemistry, 275(50), 40310‑40316.
- Clément, K., et al. (2002). Mutations in the leptin receptor gene and severe early‑onset obesity. New England Journal of Medicine, 346(24), 1763‑1769.
